Following news that the FDA had withdrawn it notice for the Cellular, Tissue, and Gene Therapies Advisory Committee meeting tentatively scheduled for July 30 to discuss the potential path forward for Capricor’s deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, Roth Capital notes shares are down about 11% today on the news. The firm, which speculates that a new Ad Comm may be forthcoming, possibly in early August, thinks the drug could still be approved by August 31, the analyst tells investors. Roth has a Buy rating and $31 price target on Capricor Therapeutics (CAPR) shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Adobe reports Q2 beat, Meta invests in Scale AI: Morning Buzz
- H.C. Wainwright cautions Capricor investors to ‘calm down’ after FDA letter
- Capricor Therapeutics put volume heavy and directionally bearish
- Capricor weakness attributed to FDA letter on advisory meeting
- Capricor Therapeutics’ Strategic Advances and Market Positioning Boost Buy Rating for Deramiocel in DMD Treatment